Recent Press Releases

WuXi PharmaTech Announces First-Quarter 2014 Results

SHANGHAI, May 14, 2014 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving the pharmaceutical, biotechnology, and medical device industries, with...

Quintiles Announces Agreement to Acquire Encore Health Resources

Acquisition Will Bolster Quintiles' Expertise in Health-Information Analytics Services and Create Foundation for Expanded Services Suite RESEARCH TRIANGLE PARK, N.C. – May 12, 2014 –...

Evotec and Eternygen enter collaboration to identify and develop novel metabolic disease therapy

Berlin and Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Eternygen GmbH, a privately owned biopharmaceutical company, today announced a drug discovery...

ICON Completes Acquisition of Aptiv Solutions

DUBLIN--ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the...

WuXi PharmaTech Begins Construction of New R&D and cGMP Manufacturing Campus in Changzhou

SHANGHAI, May 8, 2014 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development (R&D) services company with operations in...

WuXi PharmaTech Completes Construction of New Materials Characterization Facility in St. Paul

SHANGHAI, May 12, 2014 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United...

Tigermed and Frontage Laboratories Announce Strategic Investment to Strengthen Global Drug Development Service Capabilities

EXTON, Pa.--Hangzhou Tigermed Consulting Co., Ltd. (hereafter 'Tigermed'), a leading provider of outsourced clinical development services across China and Asia Pacific to the pharmaceutical...

ONYX COMPLETES API PROJECT WITH US DRUG DEVELOPER

UK-based contract research organisation Onyx Scientific has completed a development and API manufacturing project with US-based Neuronascent, Inc to support the company with its focus on neurologic...

AMRI Announces First Quarter 2014 Results

Contract Revenue Growth of 10% to $51.0 Million and Adjusted Diluted EPS of $0.16 Company Increases 2014 Adjusted EPS Guidance to $0.78 - $0.84 to Reflect Addition of Cedarburg Pharmaceuticals and...

Cytovance Biologics, Inc. and Selexys Pharmaceuticals, Corp. Announce Development and cGMP Manufacturing Agreement for SELK2 Drug Product

Cytovance Biologics, Inc. and Selexys Pharmaceuticals, Corp. Announce Development and cGMP Manufacturing Agreement for SELK2 Drug Product Oklahoma City, OK (May 6, 2014)-- Cytovance Biologics, Inc.,...

Avillion Announces Royalty Pharma Investment

Jim Reddoch, PhD, Royalty Pharma Executive Vice President for Research and Investments Joins Avillion Board LONDON (UK) and NEW YORK, NY (US), May 6, 2014 – Avillion LLP, a company focused on...

Huntingdon Life Sciences Acquires Harlan Laboratories

HUNTINGDON, England -- Huntingdon Life Sciences announced today that it has acquired Harlan Laboratories. The new company will have two operating divisions: Research Models and Services and Contract...

TrialNetworks Joins the DrugDev Family of Technology-Driven Solutions to Advance the Common Goal of Enabling More Efficient Clinical Trials

Audubon, PA and Newton, Mass. - May 5, 2014 - DrugDev, the industry's largest global network of active clinical trial doctors, today announced its acquisition of TrialNetworks. The award-winning...

WuXi PharmaTech Facilities for Late - and Commercial-Stage Analytical and Stability Testing and Clinical-Trial Materials Manufacturing Pass FDA Audit

SHANGHAI -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today...

COVANCE LAUNCHES NEW BRAND: SOLUTIONS MADE REAL™

PRINCETON, N.J. -- Covance Inc. (NYSE: CVD), the world's most comprehensive drug development company, today announced its new brand, Solutions Made RealTM. This brand strategy more effectively...

Covance Reports First Quarter Net Revenue Growth Of 6.9% To $620 Million, Pro Forma EPS Growth Of 20.1% To $0.90 And Adjusted Net Orders Of $710 Million

PRINCETON, N.J. -- Covance Inc. (NYSE: CVD) today reported results for its first quarter ended March 31, 2014. Net revenue was $620 million, representing 6.9% growth from the first quarter of 2013....

Charles River Laboratories Announces First-Quarter 2014 Results from Continuing Operations

– First-Quarter Sales of $299.4 Million – – First-Quarter GAAP Earnings per Share of $0.67 and Non-GAAP Earnings per Share of $0.82 – – Raises Sales and Non-GAAP EPS...

Quintiles Reports First Quarter 2014 Results

Over $1.0 billion of service revenues representing 8.4% growth; Integrated Healthcare Services segment grew service revenues by 6.0% in the quarter Net new business wins of $1.27 billion...

PAREXEL International Reports Third Quarter Fiscal Year 2014 Results

-- Company increases Fiscal Year 2014 revenue and EPS guidance -- 8.3% year-over-year growth in third quarter consolidated service revenue to $492.4 million -- Gross margin of 34.4%, up 300 basis...

ICON Reports First Quarter 2014

Quarter 1 net revenue increased 10% year on year to $350 million. Income from operations was $43.0 million or 12.3% of revenue. Earnings per share were 57 cents. Gross Business wins were $494...